Researchers at the University of Texas Medical Branch have developed a single-dose mRNA vaccine that provides full protection against the lethal Andes hantavirus in animal models. This breakthrough is critical for biotechnology professionals as it validates a rapid-response platform for infectious diseases capable of human-to-human transmission where multi-dose regimens are logistically impossible. Successful transition to human trials could establish these mRNA modalities as vital post-exposure tools for intercepting viral replication during active outbreaks.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.





